News

A pooled analysis of 3 studies showed that there was an extended treatment benefit for patients with FRα positive recurrent ovarian cancer treated with the novel antibody-drug conjugate mirvetuximab soravtansine.

Following positive results and FDA action on pidnarulex in BRAC 1/2-positive ovarian cancer, a phase 1 study is exploring the agent in metastatic castration-resistant prostate cancer, in combination with talazoparib.

Leading local cancer center expands clinic reach to Laclede County with a new location.

Eytan M. Stein, MD, defines Menin inhibition and its role in the leukemia space.

A phase 1/2 study of ZN-c3, encorafenib, and cetuximab in patients with BRAF V600E-mutated colorectal cancer will begin, led by Zentalis Pharmaceuticals and Pfizer.

According to results from the SIERRA trial, Iomab-B may be an effective choice for patient with relapsed or refractory acute myeloid leukemia who are 55 years of age or older.

In a first-in-human trial, a peptide-drug conjugate showed tolerability and antitumor activity in patients with advanced solid tumors.

Florida Cancer Specialists & Research Institute, LLC has submitted an application to participate in Medicare’s Enhancing Oncology Care Model, an alternative payment model that aims to address healthcare inequities, reduce costs, and improve and report outcomes for cancer patients.

Considering the higher-than-average rate of liver cancer in Texas as a whole, it was unexpected that the Kashmere Gardens neighborhood cluster would be linked to environmental issues. Texas Department of State Health Services and the City of Houston confirm the cluster exists and is caused by toxins polluted into the soil by The Union Pacific Railroad.

Richard S. Finn, MD, discusses the background on lenvatinib and what led to the development of the LEAP-002 trial.

In the prespecified interim analysis of the COMMANDS trial for low-risk myelodysplastic syndromes, luspatercept had statistically significant and clinically meaningful improvements in red blood cell transfusion independence with no new safety signals.

Cristian Tomasetti, discusses the role of circulating tumor-DNA after surgery in patients with stage II colon cancer.

In a unanimous vote, the FDA’s Oncologic Drugs Advisory Committee has voted that there is not enough evidence to conclude omburtamab improves overall survival in neuroblastoma with central nervous system/leptomeningeal metastases.

Physicians, clinicians and senior leaders of Florida Cancer Specialists & Research Institute, LLC will continue their long history of active involvement with the Florida Society of Clinical Oncology at the FLASCO Fall Session being held in Orlando, Oct. 28 & 29.

Positive efficacy and safety results from the phase 3 EPCORE™ NHL-1 trial have lead to an FDA application for approval of epcoritamab to treat relapsed or refractory large B-cell lymphoma.

In an interview with Targeted Oncology, Alfred L. Garfall, MD, discussed the FDA approval of teclistamab, the MajesTEC-1 trial, and how this information should be used in the future.

Carolyn Owen, MD, discusses how the treatment landscape has shifted in chronic lymphocytic leukemia.

In an interview with Targeted Oncology, Nicholas J. Short, MD, discussed the evolution of the treatment landscape for acute lymphoblastic leukemia and what he hopes is next to come.

Additional findings fro the phase 2 SOLO2 study shows that there is a need for research to determine the optimal strategy for patients who relapse after treatment with a PARP inhibitor.

The phase 3 CHART study reveals better survival with rezvilutamide plus androgen deprivation therapy vs bicalutamide and androgen deprivation therapy in metastatic, hormone-sensitive prostate cancer.

Early results from the phase 1 JEWEL-101 study show XB002 is well-tolerated in patients with advanced solid tumors.

Gene G. Finley, MD, explains the use of conventional chemotherapy in the small cell lung cancer space.

Despite the small number of patients enrolled, the confirmatory phase 3 LIGHTHOUSE study of melphalan flufenamide in patients with relapsed/refractory multiple myeloma demonstrates promising safety and efficacy.

Srdan Verstovsek, MD, PhD, discusses the increased thrombotic risk and management for patients with essential thrombocythemia.

In an interview with Targeted Oncology, Philippe Barthelemy, MD, discussed the preliminary findings of the AVENANCE trial of avelumab in patients with advanced or metastatic urothelial carcinoma.

Florida Cancer Specialists & Research Institute has appointed Josh Eaves as Chief Development & Strategy Officer, reporting to Chief Executive Officer Nathan H. Walcker.

Andreas Saltos, MD, discusses what he anticipates future research will examine regarding treatment options for EGFR and KRAS-mutated non-small cell lung cancer.

A progression-free survival advantage and trend toward overall survival benefit has been demonstrated in the CAPItello-291 study of capivasertib and fulvestrant for the treatment of hormone receptor-positive, HER2-low or negative locally advanced or metastatic breast cancer.

The risk of progression or death in post-menopausal patients with estrogen receptor-positive locally advanced or metastatic breast cancer was reduced with camizestrant in the SERENA-2 study.

With all patients with solid tumors enrolled in the phase 1 study of QBS72S, 2 more studies evaluating the agent in brain malignancies will commence.